WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: An overview

Pathologica

Volumn 102, Issue 3, 2010, Pages 83-87

  Sabattini, E ^a   Bacci, F ^a   Sagramoso, C ^a   Pileri, S A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Classification; Leukaemias; Lymphomas

Indexed keywords

BLOOD DISEASE; CLASSIFICATION; HUMAN; LYMPHOMA; REVIEW; WORLD HEALTH ORGANIZATION;

HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOMA; WORLD HEALTH ORGANIZATION;

EID: 77956925717     PISSN: 00312983     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2008.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2001.
3. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
4. Del Giudice I, Pileri SA, Rossi M, Sabattini E, Campidelli C, Starza ID, et al. Histopathological and molecular features of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly. Br J Haematol 2009;144:726-31.
5. Niitsu N, Okamoto M, Nakamine H, Hirano M. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sei 2010;101:1309-13.
6. Shimoyama Y, Asano N, Kojima M, Morishima S, Yamamoto K, Oyama T, et al. Age-related EBV-associated B-cell lymphoproliferative disorders: diagnostic approach to a newly recognized clinicopathological entity. Pathol Int. 2009;59:835-43.
7. Cohen Jl, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting. Ann Oncol 2009;20:1472-82.
8. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008;112:1600-9.
9. Rodríguez Pinilla SM, Roncador G, Rodríguez-Peralto JL, Mollejo M, García JF, Montes-Moreno S, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol 2009;33:81-90.
10. Beltraminelli H, Leinweber B, Kerl H, Cerroni L. Primary cutaneous CD4+ small-Zmedium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am. J Dermatopathol 2009;31:317-22.
11. Hockley SL, Giannouli S, Morilla A, Wotherspoon A, Morgan GJ, Matutes E, et al. Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol 2010;148:666-9.
12. Kanellis G, Mollejo M, Montes-Moreno S, Rodriguez-Pinilla SM, Cigudosa JC, Algara P, et al. Splenic diffuse red pulp small Bcell lymphoma: revision of a series of cases reveals characteristic clinico-pathologicalfeatures. Haematologica 2010;95:1122-9.
13. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell. lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114:3533-7.
14. Tauro S, Cochrane L, Lauritzsen GF, Baker L, Delabie J, Roberts C, et al. Dose-intensified treatment of Burkitt lymphoma and Bcell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (< 50years): a comparison of two adapted BFM protocols. Am. J Hematol 2010;85:261-3.
15. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Cin PD, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large Bcell lymphoma. Am J Surg Pathol 2010;34:327-40.
16. Burnett AK, Hills RK, Green C, Jenkinson S, Koo K, Patel Y, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocyte acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPMl, FLT3, and CEBPA. Blood 2010;115:948-56.
17. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 2009;27:171-81.
18. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:596-604.
19. Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W, et al. Multilineage dysplasia has no impact on biological, clinicopathological and prognostic features of AML with mutated nucleophosmin (NPM1). Blood 2010;115:3776-86.
20. Jegalian. AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol 2009;16:392-404.
21. Facchetti F, Pileri SA, Agostinelli C, Martelli MP, Paulli M, Venditti A, et al. Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm. Haematologica 2009;94:285-8.
22. Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic andphenotypic variability in a series of 33 patients. Am J Surg Pathol 2010;34:75-87.